Hepatitis B Market

• As per DelveInsight, the Hepatitis B Market size is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies in the market and the rise in the number of cases. 
• Several major pharma and biotech companies such as Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm, among others, are actively working in the Hepatitis B Market.
• In February 2024, the US FDA granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB).
• In August 2023, AusperBio Announces FDA clearance Of Investigational New Drug (IND) application of AHB-137 In Chronic Hepatitis B treatment.

Download the Sample PDF to Get More Insight @ Hepatitis B Market

DelveInsight's "Hepatitis B Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hepatitis B, historical and forecasted epidemiology as well as the Hepatitis B market therapeutics trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hepatitis B market report provides current treatment practices, emerging drugs, Hepatitis B market share of the individual therapies, current and forecasted Hepatitis B market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hepatitis B treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hepatitis B market.

Hepatitis B Treatment Market

Hepatitis B is a viral infection that primarily affects the liver, caused by the hepatitis B virus (HBV). It can lead to both acute and chronic illness. The virus is transmitted through contact with infectious blood or body fluids of an infected person. This can happen through various means such as sexual contact, sharing needles, being born to an infected mother, or exposure to contaminated blood.

The infection can range from being asymptomatic to causing severe liver disease. Symptoms of acute hepatitis B can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, joint pain, and jaundice (yellowing of the skin and eyes). While most adults who get hepatitis B recover fully, some people, especially infants and children, may develop a chronic infection that can lead to serious complications like liver cirrhosis, liver cancer, or liver failure later in life.

Hepatitis B Causes and Risk Factors

Hepatitis B is caused by the Hepatitis B virus (HBV), which is transmitted through contact with infected blood or bodily fluids. It can be contracted through unprotected sex, sharing needles, from an infected mother to her baby during childbirth, or through exposure to infected blood. Risk factors include living in regions where HBV is prevalent, engaging in high-risk behaviors, healthcare work involving exposure to blood, and having multiple sexual partners.

Hepatitis B Signs and Symptoms

Many people with Hepatitis B might not display symptoms for years, while others may experience acute symptoms shortly after infection. Symptoms can include fatigue, abdominal pain, jaundice (yellowing of the skin and eyes), dark urine, joint pain, nausea, and loss of appetite. Chronic Hepatitis B can lead to liver damage, cirrhosis, and an increased risk of liver cancer.

Hepatitis B Diagnosis

Diagnosing Hepatitis B involves blood tests that detect HBV antigens and antibodies. These tests determine if the virus is present, assess the stage of infection (acute or chronic), and measure the extent of liver damage. Additional tests, such as liver function tests and imaging studies, may be performed to evaluate liver health.

Treatment Options in the Hepatitis B Therapeutics Market

Treatment for Hepatitis B depends on the stage of the infection. Acute Hepatitis B may not require specific treatment, as the body can clear the virus on its own in many cases. However, for chronic Hepatitis B, antiviral medications like nucleoside/nucleotide analogs or interferons may be prescribed to reduce viral replication, slow liver damage, and lower the risk of complications. In some cases, liver transplantation might be necessary for individuals with advanced liver disease.

Hepatitis B Epidemiology 

The Hepatitis B epidemiology section provides insights about the historical and current Hepatitis B patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hepatitis B market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hepatitis B epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Hepatitis B Epidemiology

The epidemiology segment also provides the Hepatitis B epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Get detailed insights into the historical as well as forecasted epidemiology trends in the 7MM, at: Hepatitis B Epidemiology Forecast

Hepatitis B Drug Chapters

The drug chapter segment of the Hepatitis B report encloses the detailed analysis of Hepatitis B marketed drugs and late-stage (Phase-III and Phase-II) Hepatitis B pipeline drugs. It also helps to understand the Hepatitis B clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Hepatitis B Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Hepatitis B treatment.

Hepatitis B Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Hepatitis B treatment.

Hepatitis B Market Outlook

The Hepatitis B market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hepatitis B market trends by analyzing the impact of current Hepatitis B therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Hepatitis B market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hepatitis B market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hepatitis B market size and share in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Hepatitis B market in 7MM.

The United States Market Outlook

This section provides the total Hepatitis B market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Hepatitis B market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Hepatitis B market size and market size by therapies in Japan is also mentioned.

Hepatitis B Drugs Uptake

This section focuses on the rate of uptake of the Hepatitis B drugs recently launched in the Hepatitis B market or expected to get launched in the market during the study period 2019-2032. The analysis covers Hepatitis B market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Hepatitis B Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Hepatitis B market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatitis B Pipeline Development Activities

The Hepatitis B report provides insights into Hepatitis B clinical trials within Phase II, and Phase III stage. It also analyses Hepatitis B key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Hepatitis B report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Hepatitis B emerging therapies.

Explore more about the emerging therapies and key companies actively working in the market: Hepatitis B Pipeline Insight

Hepatitis B Market Growth Factors

Factors driving the Hepatitis B market include increased awareness about the disease, leading to more screening and diagnosis efforts. Advancements in antiviral therapies and the development of newer and more effective medications for Hepatitis B contribute to market growth. Efforts to improve access to vaccinations and treatments, especially in regions with a high prevalence of Hepatitis B, also impact market expansion. Additionally, ongoing research into novel therapeutic approaches and strategies for preventing Hepatitis B transmission further drives growth in the market for Hepatitis B treatments and preventive measures.

Reimbursement Scenario in Hepatitis B

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Hepatitis B market trends, we take KOLs and SMEs ' opinion working in the Hepatitis B domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hepatitis B market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hepatitis B Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Hepatitis B Market Report

• The report covers the descriptive overview of Hepatitis B, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Hepatitis B epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Hepatitis B is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Hepatitis B market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatitis B market

Hepatitis B  Market Report Highlights

• In the coming years, the Hepatitis B market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis B R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Hepatitis B. The launch of emerging therapies will significantly impact the Hepatitis B market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hepatitis B
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hepatitis B Report Insights

• Hepatitis B Patient Population
• Hepatitis B Therapeutic Approaches
• Hepatitis B Pipeline Analysis
• Hepatitis B Market Size and Trends
• Hepatitis B Market Opportunities
• Impact of Upcoming Hepatitis B Therapies

Hepatitis B Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Hepatitis B Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Hepatitis B Market
• Hepatitis B Drugs Uptake

Hepatitis B Report Assessment

• Current Hepatitis B Treatment Practices
• Unmet Needs in the Hepatitis B Market
• Hepatitis B Pipeline Product Profiles
• Hepatitis B Market Attractiveness
• Hepatitis B Market Drivers
• Hepatitis B Market Barriers

Key Questions Answered In The Hepatitis B Market Report:

Hepatitis B Market Insights:

• What was the Hepatitis B drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Hepatitis B total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Hepatitis B market size during the forecast period (2019-2032)?
• At what CAGR, the Hepatitis B market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Hepatitis B market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Hepatitis B market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Hepatitis B Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Hepatitis B?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Hepatitis B patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Hepatitis B in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hepatitis B?
• Out of all 7MM countries, which country would have the highest prevalent population of Hepatitis B during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Hepatitis B Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Hepatitis B treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Hepatitis B in the USA, Europe, and Japan?
• What are the Hepatitis B marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Hepatitis B?
• How many therapies are in-development by each company for Hepatitis B treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Hepatitis B treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hepatitis B therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis B and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Hepatitis B?
• What are the global historical and forecasted market of Hepatitis B?

Reasons to buy Hepatitis B Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the Hepatitis B market
• To understand the future market competition in the Hepatitis B market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Hepatitis B in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Hepatitis B market
• To understand the future market competition in the Hepatitis B market